Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Novo Nordisk (NYSE:NVO) released new clinical trial data from higher dose and oral Wegovy, including OASIS 4 and STEP UP, presented at ECO2026.
The trials report significant weight loss, improved physical function, and benefits across diverse patient groups, including older adults.
Results indicate better efficacy and tolerability for oral Wegovy compared with orforglipron, reinforcing Novo Nordisk’s position in obesity treatment.
Novo Nordisk, known for its diabetes and obesity therapies, is now putting fresh clinical evidence for Wegovy at the center of the obesity treatment story. With extensive new data from OASIS 4 and STEP UP, the company is giving investors and regulators more detail on how higher dose and oral formulations perform in real patients. This comes as obesity drugs draw intense interest across healthcare and broader equity markets.
For investors tracking NYSE:NVO, the key point is how this evidence may influence views on the durability and breadth of Wegovy use, beyond the initial launch phase. As payers, clinicians, and regulators evaluate competing obesity drugs, the relative efficacy and tolerability signals versus orforglipron, along with the support for older and varied patient groups, could shape longer term expectations for Novo Nordisk’s role in this segment of the market.
Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.
NYSE:NVO Earnings & Revenue Growth as at May 2026
We’ve flagged 3 risks for Novo Nordisk. See which could impact your investment.
Quick Assessment
⚖️ Price vs Analyst Target: At US$47.08, the share price is about 2.9% below the US$48.46 analyst target, sitting close to consensus.
✅ Simply Wall St Valuation: Shares are described as trading 53.7% below estimated fair value, which flags a large valuation gap.
✅ Recent Momentum: The stock is up 24.0% over the last 30 days, showing strong short term interest around the Wegovy data.
There is only one way to know the right time to buy, sell or hold Novo Nordisk. Head to the Simply Wall St’s company report for the latest analysis of Novo Nordisk’s Fair Value.
Key Considerations
📊 Wegovy trial results support Novo Nordisk’s obesity focus, which sits alongside a P/E of 10.9 versus an industry average of 15.3.
📊 Watch how payers, regulators, and prescriptions for higher dose and oral Wegovy trend against the current US$47.08 price and analyst range of US$27.54 to US$69.86.
⚠️ Balance sheet strength and dividend quality matter here, as the company carries high debt and the 3.91% dividend is not well covered by free cash flow.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Novo Nordisk analysis. Alternatively, you can check out the community page for Novo Nordisk to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NVO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com